Fate Therapeutics (FATE) Misses Q1 EPS by 4c

Fate Therapeutics (NASDAQ: FATE) reported Q1 EPS of ($0.29), $0.04 worse than the analyst estimate of ($0.25).

For earnings history and earnings-related data on Fate Therapeutics (FATE) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• BofA lists top 5 themes driving next $1tn in incremental semi sales
• Morgan Stanley upgrades CDW on stronger AI-driven server demand